Patryk Krzeminski1, María E Sarasquete2, Irena Misiewicz-Krzeminska3, Rocío Corral2, Luis A Corchete2, Ana A Martín2, Ramón García-Sanz2, Jesús F San Miguel4, Norma C Gutiérrez5. 1. Servicio de Hematología, Hospital Universitario, IBSAL, IBMCC (USAL-CSIC), Salamanca, Spain. Electronic address: patrykk@usal.es. 2. Servicio de Hematología, Hospital Universitario, IBSAL, IBMCC (USAL-CSIC), Salamanca, Spain. 3. Servicio de Hematología, Hospital Universitario, IBSAL, IBMCC (USAL-CSIC), Salamanca, Spain; National Medicines Institute, Warsaw, Poland. 4. Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Pamplona, Navarra, Spain. 5. Servicio de Hematología, Hospital Universitario, IBSAL, IBMCC (USAL-CSIC), Salamanca, Spain. Electronic address: normagu@usal.es.
Abstract
CONTEXT: MiR-155 plays a critical role in the development of B-cell malignancies. Previous studies have shown a deregulation of miR-155 in specific cytogenetic subtypes of multiple myeloma (MM). However, the mechanisms that regulate miR-155 expression in MM are not fully understood. OBJECTIVE: In the present study, we explored the regulation of miRNA-155 in MM by DNA methylation mechanisms and the impact of miR-155 expression in survival of MM patients. METHOD: Primary samples were obtained from 95 patients with newly diagnosed myeloma. Methylation was analyzed by Methylation Specific PCR, sequencing of bisulfite treated DNA and luciferase assay. RESULTS: qRT-PCR analysis revealed that miR-155 was differentially expressed in MM and its upregulation was associated with longer survival. DNA methylation of CpG island present in the first exon of miR-155 host gene was associated with its low expression in MM cell lines and patient samples. Our results showed for the first time that in vitro methylation of part of the promoter and first exon abrogated the miR-155 expression. We further showed that miR-155 expression in MM cell lines was increased by demethylating 5-aza-dC treatment and decreased by RNA-directed DNA methylation. Additionally, we found that LPS "immunological challenge" was insufficient to induce miR-155 expression in MM cell lines with methylated DNA around transcription start site (TSS). CONCLUSION: This study provides evidence that DNA methylation contributes to miR-155 expression in myeloma cells. Interestingly, the survival data showed an association between miR-155 expression and outcome of MM.
CONTEXT: MiR-155 plays a critical role in the development of B-cell malignancies. Previous studies have shown a deregulation of miR-155 in specific cytogenetic subtypes of multiple myeloma (MM). However, the mechanisms that regulate miR-155 expression in MM are not fully understood. OBJECTIVE: In the present study, we explored the regulation of miRNA-155 in MM by DNA methylation mechanisms and the impact of miR-155 expression in survival of MM patients. METHOD: Primary samples were obtained from 95 patients with newly diagnosed myeloma. Methylation was analyzed by Methylation Specific PCR, sequencing of bisulfite treated DNA and luciferase assay. RESULTS: qRT-PCR analysis revealed that miR-155 was differentially expressed in MM and its upregulation was associated with longer survival. DNA methylation of CpG island present in the first exon of miR-155 host gene was associated with its low expression in MM cell lines and patient samples. Our results showed for the first time that in vitro methylation of part of the promoter and first exon abrogated the miR-155 expression. We further showed that miR-155 expression in MM cell lines was increased by demethylating 5-aza-dC treatment and decreased by RNA-directed DNA methylation. Additionally, we found that LPS "immunological challenge" was insufficient to induce miR-155 expression in MM cell lines with methylated DNA around transcription start site (TSS). CONCLUSION: This study provides evidence that DNA methylation contributes to miR-155 expression in myeloma cells. Interestingly, the survival data showed an association between miR-155 expression and outcome of MM.
Authors: Antonella Caivano; Francesco La Rocca; Vittorio Simeon; Marco Girasole; Simone Dinarelli; Ilaria Laurenzana; Angelo De Stradis; Luciana De Luca; Stefania Trino; Antonio Traficante; Giovanni D'Arena; Giovanna Mansueto; Oreste Villani; Giuseppe Pietrantuono; Luca Laurenti; Luigi Del Vecchio; Pellegrino Musto Journal: Cell Oncol (Dordr) Date: 2016-10-19 Impact factor: 6.730
Authors: Patryk Krzeminski; Luis A Corchete; Juan L García; Lucía López-Corral; Encarna Fermiñán; Eva M García; Ana A Martín; Jesús M Hernández-Rivas; Ramón García-Sanz; Jesús F San Miguel; Norma C Gutiérrez Journal: Oncotarget Date: 2016-12-06
Authors: Sotirios G Doukas; Dimitra P Vageli; George Lazopoulos; Demetrios A Spandidos; Clarence T Sasaki; Aristidis Tsatsakis Journal: Cells Date: 2020-04-21 Impact factor: 6.600
Authors: Pablo Letelier; Ismael Riquelme; Alfonso H Hernández; Neftalí Guzmán; Jorge G Farías; Juan Carlos Roa Journal: Int J Mol Sci Date: 2016-05-23 Impact factor: 5.923